The Curative Effect Analysis Of Imatinib On 58 Cases Of Chronic Myelogenous Leukemia In Chronic Phase

Objective: To explore the relative factors affecting molecular reactions through analyzing the efficacy and safety of imatinib in the treatment of 58 CML-CP patients.Methods: A total of 58 patients with newly diagnosed CML-CP were collected from hematology out-patient department and ward of affiliated hospital of Zunyi Medical College from January 2010 to January 2016.All patients were treated by continuous oral administration of imatinib 200 mg or 400 mg once daily.The relevant factors to the molecular curative effects were analyzed through observation of hemogram,clinical feature,BCR/ABL transcription alteration,and drug toxic and side effects during treatment among patients treated with imatinib over one year.Results: Among 58 patients with newly diagnosed CML-CP after treatment with imatinib for 12 months,there were 19 patients(32.76%)with BCR/ABLIS(27)0.1%(optimal response),16 patients(27.59%)with BCR/ABLIS(29)0.1% and ?1%(warning),and 23 cases(39.65%)with BCR/ABLIS(29)1%(treatment failure).58 patients enrolled hematologic reactions during the observation period(12 months),grade III and IV granulocytopenia occurred in 23patients(39.65%),and grade IV granulocytopenia occurred in 12 patients.Grade III and IV thrombocytopenia occurred in 14 patients(24.14%),and grade IV thrombocytopenia occurred in 7 patients.Both grade III granulocytopenia and grade III thrombocytopenia occurred in 7 patients.In non-hematological adverse reactions,facial and bilateral lower extremity edema occurred in 16 cases(27.59%),gastrointestinal reactions occurred in 14cases(24.14%),rash occurred in 11 cases(18.97%),and joint pain and muscle spasms occurred in 8 cases(13.17%).Single factor analysis showed that whether medications were regular or not(drug discontinuance ?1 month and drug discontinuance <1 month,P=0.005)and whether grade III and IV thrombocytopenia occurred or not(occurrence and no occurrence,P=0.014)were the relative factors affecting molecular reactions during treatment.Whether grade III and IV thrombocytopenia occurred or not(occurrence and no occurrence,P=0.025)was the relative factor of PFS.Conclusion: The optimal response rate is 32.76% after 12 months of imatinib treatment in 58 patients with newly diagnosed CML-CP,expected treatment results have not been achieved,and it may be associated with bad compliance,financial difficulties,and inadequate propaganda and education of medical staff.Whether medications are regular or not and whether grade III and IV thrombocytopenia occur or not are the relative factors affecting molecular reactions,and whether grade III and IV thrombocytopenia occurr or not is the relative factor of PFS.